UI Hospitals and Clinics

Clinical Trial Details

Short Title
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Official Title

Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Description

Participants in this study have been diagnosed with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). There are two treatment groups, one will receive the study drug called ibrutinib and the second group will receive a placebo. The purpose of the study is to assess the effects (both good and bad) of ibrutinib in patients with CLL or SLL and whether the CLL or SLL responds to this treatment.

Start Date
January 8, 2013
End Date
January 9, 2014
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Brian Link, MD
Contact Info

Mary Schall, 319-356-3516

Department
Department or Field of Study
Keywords
cancer ; Chronic Lymphocytic Leukemia (CLL) ; Enter keyword ; ibrutinib ; IRB#201207510 ; linkb ; phase 3 ; phase III ; Small Lymphocytic Lymphoma (SLL) ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.